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Abstract
Background: Identifying and monitoring high-risk patients can aid the prevention of esophageal cancer (EC). The
interaction of environmental risk factor exposure and genetic susceptibility may contribute to the etiology of EC.
Biotransformation enzymes such as Glutathione S-Transferases (GSTs ) detoxify mutagenic and genotoxic compounds and
therefore control the rate of detoxification of carcinogens. Functional polymorphisms in the genes coding for GSTs alter
their enzyme activity in vitro, and were reported to modify EC risk in Asians. We hypothesized that altered enzyme activity
GST genotypes influence the susceptibility for esophageal adeno- (EAC) and squamous cell carcinoma (ESCC) in Caucasians.
Methods: We performed a case–control study including 440 Caucasian patients with EC and 592 healthy Caucasian
controls matched for age and sex. Functional polymorphisms were selected and genotypes were determined in GST
classes Alpha, Mu, Theta and Pi by means of polymerase chain reaction. Genotypes were classified into predicted high,
intermediate and low enzyme activity categories based on in vitro activity data. The distribution of the activity genotypes
were compared between patients with EAC or ESCC, and controls. Odds ratios (OR) with 95% confidence intervals (CI) were
calculated by logistic regression analyses. Gene-gene interactions were tested and for comparison purposes, the predicted
low and intermediate activity genotypes were combined. Genotypes with similar risks for EAC or ESCC were combined and
analyzed for multiplicative effects.
Results: Our analyses includes 327 patients with EAC and 106 patients with ESCC. Low or intermediate activity enzyme
genotypes for GSTM1, GSTA1, GSTP1 I105V and A114V as well as for GSTT1, did not significantly modify the risk for ESCC or
EAC in our Dutch population.
Conclusion: Functional genotypes in GST genes are not involved in EAC or ESCC susceptibility in Caucasians, in contrast to
results on ESCC from Asia or Africa.
Background
Esophageal Cancer (EC) has limited treatment options
resulting in poor 5-year survival rates of 15% [1] and it
holds one of the highest cancer mortality rates [2]. The
leading global histological subtype used to be esophageal
squamous cell carcinoma (ESCC), but in Western coun-
tries a rapid increase in adenocarcinoma has occurred
over the past decennia [3]. To a large extent this devel-
opment is due to the increase in prevalence of gastro-
esophageal reflux disease (GERD) and obesity, two
significant determinants of esophageal adenocarcinoma
(EAC) [3]. Risk factors as smoking and alcohol con-
sumption are significantly related to ESCC and contrib-
ute to the still dominating position of this subtype in
Asia [3]. Exposure to environmental risk factors alone
cannot explain all cases of esophageal carcinoma, genetic
predisposition appears to play a role as well. Detoxifica-
tion enzymes biotransform carcinogens and toxic agents
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into less active and water-soluble compounds ready for
excretion with bile, urine or faeces. The activity of phase
I and II enzymes determine the rate of detoxification of
carcinogens in cells and tissues.
Glutathione S-transferases (GSTs) are important phase
II biotransformation enzymes catalyzing the nucleophilic
addition of glutathione to xenobiotics, oxidative stress
products and phase I electrophilic and carcinogenic me-
tabolites [4]. Allelic variation in GST genes affects in vivo
enzyme activity and subsequently decrease the rate of car-
cinogen detoxification. The GST family has a widely vari-
able organ distribution and four classes of GSTs; Alpha,
Mu, Theta and Pi, are known to have esophageal expres-
sion [5]. The high level of esophageal expression, poly-
morphic nature of the GST genes and the wide range of
carcinogenic substrates, make it all very plausible that this
superfamily of detoxification enzymes may influence
esophageal carcinoma susceptibility.
Many studies addressing this issue originate from Asia
and as a result ESCC has been widely studied as summa-
rized in a recent meta-analysis [6]. To a lesser extend
EAC cases have been included in studies, along with
Barrett’s esophagus (BE). BE is suggested to be the histo-
logical precursor of EAC, displaying metaplastic colum-
nar epithelium and sharing GERD and obesity as risk
factors [7]. It was demonstrated that there is a decreased
GST enzyme activity or expression following the se-
quence; normal esophageal epithelium, Barrett’s meta-
plasia, dysplasia, adenocarcinoma [8,9], suggesting an
early etiological role for this enzyme system. Studies
examining the role of functional polymorphisms in the
GST genes expressed in the esophagus (classes Alpha,
Mu, Theta and Pi) in relation to EAC risk are lacking.
This study was set out to examine whether (combined)
GST genotypes with altered predicted enzyme activities,
modified EAC and ESCC risk in Caucasians. We
conducted a case–control study between 2002 and 2012
on 440 patients with EC and 592 age and sex matched
controls of the Caucasian race.
Methods
Patients with EC and controls
The study was approved by the Medical Ethical Review
Committee, region Arnhem-Nijmegen (CMO 2002/114).
From 2002 to March 2012, 349 EDTA blood samples
from Caucasian patients with esophageal carcinoma
were collected from 4 hospitals within 30 km distance in
the South-East area of the Netherlands [10]. For some
EC cases (n = 91) no blood was available as source of
DNA and in these cases DNA was isolated from normal
esophageal or gastric tissue, obtained after surgery [10],
so in total 440 EC cases could be evaluated. Patients
were included in the order of entry to the hospitals. Also
592 EDTA blood samples from healthy controls,
matched as a group for age, Caucasian race, gender and
geographical location, were recruited after advertisement
in local papers, as described earlier [10]. Only patients
with a diagnosis of esophageal carcinoma, as confirmed
by a pathologist, were included in the study. Tissue,
blood and DNA were stored, and DNA isolation was
performed as previously described [11].
Esophageal GST classes and genotyping
GST classes were selected on the basis of possible rele-
vance to esophageal carcinoma etiology, expression in
esophageal mucosa, and significance as revealed in Asian
case–control studies on ESCC risk [6]. Only functional
polymorphisms were chosen for genotyping, again based
on possible relevance for EC susceptibility.
Genotypes as well as the sequences of the primers and
probes are depicted in Table 1. The GSTM1 isozyme con-
tains three main genotypes at its locus on chromosome
1p13: GSTM1*a, GSTM1*b and GSTM1*0. GSTM1*a and
GSTM11*b differ only at base position 519 by a G > C re-
placement which results in a K >N substitution at codon
173. This has no effect on the catalytic properties of the
respective enzymes. However, presence of the GSTM1*0
allele results in a protein absence and homozygosity of
GSTM1*0 (GSTM1 null genotype) results in an absence of
enzyme activity [4]. The deletion polymorphism was ex-
amined through melt curve analysis [12].
The glutathione S-transferase Alpha gene has four
functional polymorphisms in full linkage disequilibrium;
-631T, -567T, -69C, -52G designated as allele GSTA1*a
and -631G, -567G, -69T, -52A designated as allele
GSTA1*b. Genotypes were determined via the PCR and
restriction enzymes methodology as described by Coles
et al. [13].
Chromosome 11q13 is the locus for the GSTP1 gene.
A base pair (A > G) substitution at nucleotide 313 results
in the amino-acid substitution Isoleucine (I) to Valine
(V) at codon 105. In addition, the C > T substitution at
nucleotide 341 creates a change in amino-acid transcrip-
tion at codon 114: Alanine (A) to Valine (V). The GSTP1
variant alleles express a protein with an altered enzyme
activity and substrate specificity [14]. GSTP1 polymor-
phisms were determined by using the CFX96 Real Time
PCR Detection System (Bio-Rad Hercules, CA, USA).
DNA samples were amplified by PCR and detection was
performed using sequence specific DNA-probes. Primers
and probes for detection of the polymorphisms (Table 1)
were designed using Beacon designer software (PREM-
IER Biosoft International, Palo Alto, CA, USA) and syn-
thesized by Sigma Aldrich (St. Louis, MO, USA). For
Real Time PCR, the DNA was denatured at 95°C for 3
min, followed by 40 cycles of 30 sec at 95°C, 30 sec at
annealing temperature (Table 1) and 30 sec elongation
at 72°C. Analysis was performed by the Bio-Rad CFX
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Manager detection software for Windows version 2.0
(Bio-Rad Hercules). The intensity of the mutant probe
signal (HEX) was plotted against the wild type probe
signal.
The GSTT1 gene is located on chromosome 22q11 and
contains 2 variant alleles. The GSTT1*0 allele results in a
gene deletion and expresses no enzyme activity, while the
wild type allele GSTT1*1 is fully active [15]. The deletion
polymorphism was determined via melt curve analysis
[15]. However, due to the nature of the polymorphism in
GSTM1 and GSTT1, the distinction between heterozygous
and homozygous functional genotypes cannot be made by
our analyses. Only the homozygous variant genotype (null
genotype) can be differentiated.
Statistical analyses
The independent samples t-test was applied for the dif-
ferences in continues variables between characteristics of
patients and controls. The chi-square test was used for
analyzing nominal variables of patient characteristics
and to test for differences of frequencies in genotypes
between two groups. Logistic regression analyses were
used to calculate odds ratios (OR) with 95% confidence
intervals (95%CI). Genotypes were classified in predicted
enzyme activity groups, and the predicted high enzyme
activity group was set as reference. Stratified analyses
were performed according to tumor histology.
To test the EC risk interactions of GST genotypes, at
first the genotypes with predicted low and intermediate
enzyme activity of GSTA1, GSTP1 105 or GSTP1 114 were
combined to create two instead of three subgroups: a ref-
erence subgroup with predicted high enzyme activity ge-
notypes and a subgroup with predicted low/intermediate
enzyme activity genotypes. Then, GST genotypes associ-
ated with either a decreased risk (OR < 1) or increased risk
(OR > 1) were analyzed for interactions (Figure 1) by logis-
tic regression analyses.
All P values were two-sided and a probability level of
P < 0.05 was considered to be significant. All analyses
were performed with the software SPSS for Windows,
version 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Table 2 shows the demographics of patients and con-
trols. A total of 440 patients with esophageal cancer, 327
with EAC and 106 with ESCC, and 592 healthy controls
were included. For 7 patients the exact tumour type was
not mentioned in the pathology reports and these sam-
ples were therefore excluded from the histology stratified
analyses. Controls were matched with the whole EC
Table 1 Primers and probes and annealing temperatures for detection of GST polymorphisms
GST Polymorphism
protein change
Genotypes Primers (forward)
probes (wild type)
Primer (reverse)
probes (mutant)
Annealing temp.
MgCl2 Conc.
GSTM1 Deletion Wild Type: GSTM1 + 5’-CTC CTG ATT ATG
ACA GAA GCC-3’
5’-CTG GAT TGT AGC
AGA TCA TGC-3’
58°C
Polymorphism Hetero.: GSTM1 + 2.0 mM
Homoz.: GSTM1 -
GSTA1 −631 T > G Wild Type: GSTA1 *a/*a 5’-TGT TGA TTG TTT
GCC TGA AAT T-3’
5’-GTT AAA CGC TGT
CAC CGT CC-3’
58.5°C
−567 T > G Hetero.: GSTA1 *a/*b 2.0 mM
−69 C > T, -52 G > A Homoz.: GSTA1 *b/*b
GSTP1 313 A > G Wild Type: I-105-I 5’-CCT GGT GGA CAT
GGT GAA TGA-3’
5’-AGC CAC CTG AGG
GGT AAG-3’
64°C
105 Ile > Val Hetero.: I-105-V 5’-Fam-CGC TGC AAA
TAC ATC TCC CTC ATC
TAC A-BHQ1-3’
5’-Hex-CGC TGC AAA
TAC GTC TCC CTC ATC
TAC A-BHQ1-3’
2.5 mM
Homoz.: V-105-V
GSTP1 341 C > T Wild Type: A-114-A 5’- TGGACAGGCAGAAT
GGAATAGAG -3’
5’- GGGTCTCAAAAGGCT
TCAGTTG -3’
65°C
114 Ala > Val Hetero.: A-114-V 5’-Fam- CATCCTTGCCC
GCCTCCTGCCAGA -BHQ1-3’
5’-Hex-CATCCTTGCCCACC
TCCTGCCAGA -BHQ1-3’
3.0 mM
Homoz.: V-114-V
GSTT1 Deletion Wild Type: GSTT1 + 5’-TTC CTT ACT GGT
CCT CAC ATC TC-3’
5’-TCA CCG GAT CAT
GGC CAG CA-3’
59.5°C
Polymorphism Hetero.: GSTT1 + 2.0 mM
Homoz.: GSTT1 -
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patient group for Caucasian ethnicity, recruiting area,
age and sex. The female sex was more present in pa-
tients with ESCC in comparison to patients with EAC
(P < 0.001), and in comparison to controls (P = 0.003).
Otherwise, no significant difference was found between
the reported demographics of patients with EAC or
ESSC, and controls.
Genotypes were analyzed for both the histological sub-
groups in comparison to controls and classified into pre-
dicted enzyme activity groups (Table 3). GSTA1 and
GSTP1 polymorphisms were distributed according to the
Hardy-Weinberg equilibrium (GSTA1 controls/cases, P =
0.71/P = 0.38; GSTP1-I105V controls/cases, P = 0.27/P =
0.79; GSTP1-A114V controls/cases, P = 0.75/P = 0.97).
Table 4 depicts the odds ratios for the comparisons of
groups with predicted enzyme activity between patients
with ESCC or EAC, and controls. For GSTM1, GSTA1,
GSTP1 I105V and A114V as well as for GSTT1, the low
or intermediate activity enzyme genotypes did not sig-
nificantly modify the risk for ESCC or EAC in our
population.
The (combined) genotypes of predicted low and low/
intermediate enzyme activity (see Table 3) were analyzed
for interactions, when genotypes had similar effect sizes
(decreased or increased risk). For example, the correlation
between the combined genotypes of GSTM1 & GSTA1
was analyzed because the predicted low enzyme activity
genotypes of GSTM1 or low/intermediate genotypes of
GSTA1 both showed an OR < 1 for EAC risk (see Table 4
and Figure 1). Only the correlation of predicted low/inter-
mediate enzyme activity genotypes GSTP1 105 and
GSTA1 (P < 0.05) and GSTP1 105 and GSTT1 (P = 0.053)
showed a significant and near significant lower risk for
ESCC, respectively. The genotypes of predicted low and
intermediate GSTP1 105 & low and intermediate GSTA1
enzyme activity, and of low and intermediate GSTP1 105
& low GSTT1 were combined and set off against their cor-
responding predicted high activity genotypes, but the as-
sociations for ESCC risk failed to reach significance; OR
0.62; 95%CI 0.36 – 1.08 and 0.46; 0.20 – 1.07, respectively
(Figure 2).
Discussion
This case–control study reveals no associations between
modified activity GST genotypes and EAC or ESCC sus-
ceptibility in Caucasians. Only GSTA1 low or intermedi-
ate genoytpe was associated with a non-significant
protective effect for both tumour types, whereas the
remaining GST classes showed contradictory effect sizes
for EAC and ESCC.
Although many case–control studies investigated GST
polymorphisms and EC risk, only seven originated from
Western populations and reported on EAC risk. These
studies were from Europe [16-19], the USA [20] and
Canada [21,22]. Our results contrasts with the findings of
Casson et al. [21] and Abbas et al. [16] that the GSTP1
Ile105Val and GSTT1*1*1 genotype increased EAC risk,
ORs are 2.5; 1.0 – 6.3 and 13.3; 1.7 – 106.9, respectively.
Furthermore van Lieshout et al. [18] and Zendehdel et al.
[19] reported on both ESCC and EAC susceptibility and
found the GSPP1 variant allele to increase the risk for EAC
and ESCC, respectively. However, all studies offer inconclu-
sive results due to very low number of EAC and ESCC cases
Figure 1 GST genotype combinations. Low risk genotypes: variant genotypes associated with a decreased EAC or ESCC risk (OR < 1.0). High risk
genotypes: variant genotypes associated with an increased EAC or ESCC risk (OR > 1.0).
Table 2 Characteristics of patients and controls
Characteristics Patients Controls
ESCC EAC EC
Number (%) 106* (24.1%) 327* (74.3%) 440* (100%) 592
Age
(yrs; mean ± SD)
64.4 ± 10.5 64.9 ± 11.2 64.8 ± 11.1 63.4 ± 11.9
Gender
Male 67* (63.2%) 281 (85.9%) 348 (79.0%) 478 (80.7%)
Female 38* (35.8%) 46 (14.1%) 84 (19.1%) 114 (19.3%)
*Note that for 7 patients data on the exact tumor type are missing, whereas
for 1 patient the gender is unknown.
ESSC esophageal squamous cell carcinoma, EAC esophageal adenocarcinoma.
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(n < 100), except for the study of Murphy et al. which in-
cluded 207 EAC cases [17]. Our study includes a relatively
large EAC group and consequently may offer a higher
power.
Although there is a degree of inconsistency and
population sizes are relatively small (n = 45 and n = 234
[23,24]), ESCC risk is generally addressed by Asian
studies and reported increasing ESCC risk for the
homozygous GSTP1105Val and homozygous GSTM1*0
genotypes whereas some studies even conclude them to
be independent risk factors for ESCC in China [25-27]
and Brazil [28]. The largest studies however (n = 562 &
n = 245; [29,30]), originated from South Africa with
conflicting results, as mixed ancestry in African popula-
tions are a difficulty for genetic investigators. So although
results differ globally, our finding is in accordance with
several meta-analyses [6,31-33], concluding that GST
genotypes do not seem EC risk factors, the variant
GSTP1 105 genotypes excluded [33]. Zendehdel et al.
conducted a Swedish case–control study as well as a
meta-analysis, including only studies with Caucasians,
and stratified according to histology [19]. Interestingly,
this meta-analysis consisted of the Caucasian studies
mentioned above [16-18,20-22] and found that the GSTP1
I105V polymorphism was associated with an increased risk
for ESCC (1.4; 1.0 – 2.2) and not for EAC (1.2; 0.9 – 1.6).
However, their own data contributed largely to this
effect, as their patient numbers consisted 60% of the
pooled numbers of the meta analysis.
Table 3 GST genotype distribution according to predicted enzyme activity
GST GST genotypes Predicted enzyme activity ESCC (n = 106)# EAC (n = 327)# Controls (n = 592)#
GST M1 *1/*1 & *1/*0 High-Intermediate 48 (45.7%) 156 (47.7%) 273 (46.2%)
*0/*0 Low 57 (54.3%) 171 (52.3%) 318 (53.8%)
GST A1 *1a/*1a High 43 (41.3%) 131 (42.1%) 214 (37.2%)
*1a/*1b Intermediate 50 (48.1%) 133 (42.8%) 277 (48.2%)
*1b/*1b Low 11 (10.6%) 47 (15.1%) 84 (14.6%)
GST P1 I105V Ile / Ile High 48 (45.7%) 119 (37.5%) 246 (41.6%)
Ile / Val Intermediate 42 (40.0%) 157 (49.5%) 261 (44.2%)
Val / Val Low 15 (14.3%) 41 (12.9%) 84 (14.2%)
GST P1 A114V Ala / Ala High 92 (86.8%) 262 (82.6%) 485 (83.5%)
Ala / Val Intermediate 14 (13.2%) 52 (16.4%) 91 (15.7%)
Val / Val Low 0 3 (0.9%) 5 (0.9%)
GST T1 *1/*1 & *1/*0 High-Intermediate 87 (82.9%) 248 (75.8%) 463 (78.3%)
*0/*0 Low 18 (17.1%) 79 (24.2%) 128 (21.7%)
ESSC esophageal squamous cell carcinoma, EAC esophageal adenocarcinoma.
#Some genotyping data were missing due to PCR bias.
Figure 2 Combined low risk genotypes and ESCC susceptibility.
ESCC = Esophageal Squamous Cell Carcinoma; OR = Odds Ratio; 95%
CI = 95% Confidence Interval. GSTP1 105 = low and intermediate
activity GSTP1 105 genotypes; GSTA1 = low and intermediate activity
GSTA1 genotypes; GSTT1 = low activity GSTT1 genotype.
Table 4 Odds ratios and 95% CI according to predicted
GST enzyme activity genotypes for ESCC and EAC
patients compared to controls
GST Comparisons ESCC OR (95%CI)* EAC OR (95%CI)
GST M1 High- Intermediate Ref Ref
Low 1.06 (0.69 – 1.61) 0.94 (0.72 – 1.23)
GST A1 High Ref Ref
Intermediate 0.88 (0.56 – 1.38) 0.78 (0.58 – 1.06)
Low 0.58 (0.28 – 1.21) 0.91 (0.60 – 1.39)
GST
P1I105V
High Ref Ref
Intermediate 0.83 (0.53 – 1.29) 1.24 (0.93 – 1.67)
Low 0.92 (0.49 – 1.72) 1.01 (0.66 – (1.56)
GST
P1A114V
High Ref Ref
Intermediate 0.86 (0.47 – 1.59) 1.06 (0.73 – 1.54)
Low 1.11 (0.26 – 4.68)
GST T1 High-Intermediate Ref Ref
Low 0.80 (0.46 – 1.39) 1.15 (0.84 – 1.59)
* Odds ratios were adjusted for gender.
ESSC esophageal squamous cell carcinoma, EAC esophageal adenocarcinoma.
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So according to the literature so far, only the GSTP1
Ile105Val polymorphism seems involved in ESCC eti-
ology. Our genotype-genotype interaction analyses con-
firmed this premise, as combinations of low and
intermediate GSTA1, or low GSTT1, with low and inter-
mediate GSTP1 105 genotypes showed a trend for a de-
creased ESCC risk. Other studies on interactions mostly
examined the GSTM1 null genotype in combination
with either CYP2E1 [25,26,34] or CYP1A1 genotypes
[27]. Moaven et al. reported that interactions between
GST polymorphisms were not associated with a modify-
ing effect for ESCC in an Iranian population [35], while
Wang et al. reached similar conclusions in a Chinese co-
hort [36]. Both studies however had small patient num-
bers (n = 148 and n = 107, respectively). Larger study
sizes are warranted to investigate the effect of combined
GST genotypes, more explicitly combinations with
GSTP1 genotypes, and the risk for ESCC. Moreover,
GSTP1 is the main GST enzyme expressed in the
esophagus [9] and the genetic variants express proteins
with a large reduction of enzyme activity [37].
Another important finding clearly depicted by this
study, is the contrasting effects for ESCC and EAC risk,
possibly related to their different etiologies. An increas-
ing risk for EAC by GST genotypes may be due to a
lower detoxification rate of carcinogens. But studies ori-
ginating from South Africa [30] and Iran [38] corres-
pond with our results and also report protective effect
sizes of GST variants for ESCC risk. Matejic et al. ex-
plains this by the prevention of glutathione (GSH) deple-
tion, due to a decreased conjugation activity of the
GSTs. GSH is a powerful antioxidant and thus an opti-
mal GSH level to protect against oxidants is maintained
[30]. However, it remains difficult to clarify the differ-
ence in effect size between EAC and ESCC. Substrate
overlap between GST isozymes can compensate the de-
creased detoxification of mutagens attributable to a single
enzyme deficiency. Moreover, the risk for EAC and ESCC
is probably substrate dependent. Although substrate over-
lapping occurs for oncogenetic compounds such as Benzo
A-Pyrene-Diol-Epoxide, 1,2-epoxy-3-butene and 1,2:3,4-
diepoxybutane, there is a degree of specificity per GST
isoenzyme. The Mu, Alpha and Pi GSTs conjugate several
carcinogenic epoxides like aflatoxin B1 epoxide (a naturel
carcinogen) and polycyclic aromatic hydrocarbons diol ep-
oxide such as benzo[a]pyrene (BaP). The Theta class GST
is involved in the detoxification of small dihaloalkanes such
as dichloromethane which is an important compound used
in paint strippers, plastics and pharmaceutical drugs, and
also dibromoethane, an anti-knocking agent in gasoline.
Limitation of our study are the relatively small number
of cases involved, which after stratification according to
tumor histology, results in even lower subgroup numbers
and therefore limits the power of the study. For instance,
interactions with the GSTP1 variants showed a tendency
to modify ESCC risk, but genotype combinations failed to
reach statistical significance, which mainly may be a power
issue as the especially the ESCC group is small in our
Dutch Caucasian population. Another limitation is the
lack of data on exposure to mutagenic compounds (smok-
ing, alcohol consumption, etc.) in patients and controls, to
counterbalance confounding effects (and additionally
examine potential gene-environment effects).
Conclusion
We conducted the largest case–control study so far on
GST variant genotypes and esophageal cancer risk in a
Western population of Caucasian ethnicity. Although
this study did not detect significant associations between
altered predicted enzyme activity GST genotypes and
EAC or ESCC risk, our results indicate that gene-gene
interactions between GSTP1 variants could play a role in
EC susceptibility.
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